Rainer Wessel
Investitore di Private Equity presso EMBL Ventures GmbH
Profilo
Rainer Wessel is currently a Venture Partner at EMBL Ventures GmbH.
Previously, he worked as the President & Chief Executive Officer at Axxima Pharmaceuticals AG.
He also served as the Chief Business Officer & Executive Speaker at Ganymed Pharmaceuticals AG from 2009 to 2011.
Additionally, he worked as a Principal at QIAGEN GmbH.
Posizioni attive di Rainer Wessel
Società | Posizione | Inizio |
---|---|---|
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | Investitore di Private Equity | - |
Precedenti posizioni note di Rainer Wessel
Società | Posizione | Fine |
---|---|---|
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Ganymed Pharmaceuticals AG develops antibodies for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency, as well as mitigates the threat of toxicity. The company was founded by Özlem Türeci, Dirk L. Sebastian, Christoph Huber and Ugur Sahin in 2001 and is headquartered in Mainz, Germany. | Presidente | 05/11/2009 |
QIAGEN GmbH
QIAGEN GmbH Miscellaneous Commercial ServicesCommercial Services QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany. | Corporate Officer/Principal | - |
Axxima Pharmaceuticals AG
Axxima Pharmaceuticals AG Miscellaneous Commercial ServicesCommercial Services Axxima Pharmaceuticals AG provided drug discovery and development services. It was a drug discovery company in the field of kinase inhibition. It specialized in kinase-based drug discovery aimed at treating certain forms of cancer. It had also focussed on on HIV, Hepatitis C, tuberculosis and one particular herpes virus infections. The company was headquartered in Munich, Germany. | Presidente | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Ganymed Pharmaceuticals AG develops antibodies for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency, as well as mitigates the threat of toxicity. The company was founded by Özlem Türeci, Dirk L. Sebastian, Christoph Huber and Ugur Sahin in 2001 and is headquartered in Mainz, Germany. | Health Technology |
Axxima Pharmaceuticals AG
Axxima Pharmaceuticals AG Miscellaneous Commercial ServicesCommercial Services Axxima Pharmaceuticals AG provided drug discovery and development services. It was a drug discovery company in the field of kinase inhibition. It specialized in kinase-based drug discovery aimed at treating certain forms of cancer. It had also focussed on on HIV, Hepatitis C, tuberculosis and one particular herpes virus infections. The company was headquartered in Munich, Germany. | Commercial Services |
QIAGEN GmbH
QIAGEN GmbH Miscellaneous Commercial ServicesCommercial Services QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany. | Commercial Services |
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | Finance |
- Borsa valori
- Insiders
- Rainer Wessel